搜索
Alector Inc
ALEC添加自选
2.160USD
-0.140-6.09%
收盘 05/15, 16:00（美东）报价延迟15分钟
239.81M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-6.09%
5天
+2.86%
1月
-15.29%
6月
+74.19%
今年开始到现在
+38.46%
1年
+77.05%
TradingKey Alector Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
Alector Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名153/382位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价3.10。中期看，股价处于平稳状态。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Alector Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Alector Inc亮点
亮点风险
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
业绩增长期
公司处于发展阶段，最新年度总收入21.05M美元
估值合理
公司最新PE估值-1.82，处于3年历史合理位
机构减仓
最新机构持股89.88M股，环比减少26.83%
史蒂文·科恩持仓
明星投资者史蒂文·科恩持仓，最新持仓市值23.10K
分析师目标
根据
8
位分析师
持有
评级
3.100
目标均价
+34.78%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Alector Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Alector Inc简介
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
公司代码ALEC
公司Alector Inc
CEORosenthal (Arnon)
网址https://alector.com
相关品种
